Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
1. Adventrx Pharmaceuticals, Inc. (ANX) has grown from a $23.31 million market cap a year ago to a current market cap of $88.15 million. The company currently holds only one analyst recommendation but that recommendation is a strong buy with a price target of $16.00
SHORTING/Total Trading 300k shares do not mean anything
NO NEED TO GUESS..SEC FILLING SHOWS ANX-530 200MILLION MKTPOTENTIALS(2008)]
http://edgar.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=5948890-9464-32361&SessionID=C21oWWffLuv6Fm7
Making A Choice $3.5 to $16 not a month away!!!
ANX target raised to $16 based on ANX188
Monday June 20, 2011, 9:38 am
Rodman & Renshaw raised Adventrx's price target to $16, shares currently trade at $2.50, citing the company's ANX188 opportunity in sickle cell crises. Shares are Outperform rated.
Off loading take all women & chilren out from the boat.
What happens if you have short this and FDA announce approval and Bid goes $15
You never know similar case of KV.A and ANX .. Like in case of KV.A ..FDA approved it in 35 days in advance of PDUFA date both have same case as issue was related to to the manufacturing only and FDA has cleared for clinical or safety aspects.
Only problem with KV.A was MAKENA was the same drug as despenced trough Pharmacy so exclusivity was not granted whereas for Adventrex Exelbine is similar drug as vinorelbine BUT NOT THE SAME. So no question on exclusivity.
SIMILAR and SAME makes the whole difference.
Direction changed ...nothing can go wrong...
Pickedup another 5000..
ANX- 530 Exelbine , a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®);
Exelbine or Improved Vinorelbine would definately get FDA Approval as Vinorelbine received approval by the United States Food and Drug Administration (FDA) in December 1994 sponsored by Burroughs Wellcome Company
Drug vinorelbine was invented by the pharmacist Pierre Potier and his team from the CNRS in France in the 1980s and was licensed to the oncology department of the Pierre Fabre Group. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of non-small cell lung cancer. It gained approval to treat metastatic breast cancer in 1991.
In most European countries, vinorelbine is approved to treat non-small cell lung cancer and breast cancer.
Remember 80 million short as of June 15th and past 26 days trading has not covered more than 10-15 million shares..That means short position is still is in big problem and approval is nearing making the situation worse for those shorts...
Now another problem ..out of 26 million O/S shares 60.10% shares are with Institutions and therefore not available for trade or in float..left with hardly 8-10million shares..as FREE float..
COMING BACK TO SHORT COVERING OF MORE THAN 50-60 MILLION SHORT SELL.....HOW BROKERAGE WILL RETURN THIS SHARES TO TRANSFER AGENT OR DTC if float is 8-10million ?
PRICE OF ANX has SKY LIMIT ONCE FDA APPROVAL IS GRANTED...
At some point this Market Makers may try to frustate you but be wise investor keep patients....Shorts can act in different ways to get shares out from you,frustating you or shorting more but at the end they will have to realize the FACT...
The FACT is ANX in real sense another DNDN......PERIOD.
Shareholders meeting held on July 11th which increases issued common shares by 600million ..... O/S shares 1.2billion now
DUE YOU THINK THAT SHORT POSITION OF 80 MILLION SHARES AS OF 15TH JUNE LAST MONTH HAS BEEN COVERED....
THE ANSWER IS NO ....
USFDA approval prior to PDUFAdate...like DNDN shall give opening price $20? Remember 26million O/S shares with Institution Hold'gs: 60.10% (as of 6/1/11)and 1.38millions Insiders..
IMAGINE THAT SHORT INTEREST OF 80.93 MILLION AS OF 15TH JUNE 2011......HAS LOT MORE TO COVER...............LOT MORE Dangerous THEN YOU THINK.....CAN GO WAY BEYOUND .............!!!!!!!!!!!
We need only 180million shares needs to be controlled as more than 450 millions shares are with Insiders and LJC...
as of 15th June 2011 84% shares are short and still there is significant failure to return the shares to Transfer agent..
DO NOT WORRY FROM SHORT TRADERS....EVENTUALLY THIS HAS TO GROW...
MCET has already applied to USFDA for conducting Inhuman clinical trials on Ideal Biostent...Approval expected anytime soon..
Research and Markets: Non-Small Cell Lung Cancer (NSCLC) - Pipeline
Assessment and Market Forecasts to 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://
www.researchandmarkets.com/research/a475ef/nonsmall_cell_lun) has
announced the addition of GlobalData 's new report "Non-Small Cell
Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to
2017" to their offering.
“Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market
Forecasts to 2017”
Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market
Forecasts to 2017 is an essential source of information and analysis
on the global Non-Small Cell Lung Cancer (NSCLC) therapeutics market.
The report identifies the key trends shaping and driving the global
NSCLC therapeutics market. The report also provides insights on the
prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market
leaders. Most importantly, the report provides valuable insights on
the pipeline products within the global NSCLC sector. This report is
built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by a team of
industry experts.
Non-Small Cell Lung Cancer Therapeutics Market is Forecast to Show
High Growth till 2017
The authors estimate that the global Non-Small Cell Lung Cancer
(NSCLC) therapeutics market was valued at $4.1 billion in 2009 and
is . This high growth forecast is primarily attributed to the strong
pipeline landscape, population growth and release of new first-in-
class drugs with better safety and efficacy profiles. Low treatment
seeking, diagnosis and prescription rates and the availability of
generics with better efficacy and safety profiles, pose significant
challenges for prospective market entrants.
Two strong reason to buy...
1.sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer.
http://www.trade4all.com/view_newsletters.php?email_id=32957&thetitle=PennyTrader+Midday+Report+for+July+11%2C+2011+SMHS%2C+DEGH%2C+MCET&desc=...
2. U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease. Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528.
http://www.stockhaven.com/mcet-multicell-technologies-why-we-alerted-mcet-at-007-on-stem-cell-patent-news/
The Toronto General Research Institute is the research arm of the Toronto General Hospital.
186 researchers
266 trainees
378 technical/suport staff
267,000 square ft research space
726 total publications
$65,570,000 external funding
http://www.uhnresearch.ca/institutes/tgri/index.htm
If we hear from Toronto Gen Hospital on Recruitment of Patients for Clinical trials on MCT465...All shorts will get hospitalized with death certificate...
Compare with Provenge DNDN $40 and MCT465
http://www.multicelltech.com/Therapeutic-Pipeline/MCT-465
SHORT SQEEZE AFTER 87MILLION SHARES TRADE?
Better you cover now many eyes on NEOM..
Moving up!!! Power Hr?
You will be late everyday...as 100% approval and this could go upto $10
NEOM ISSUED 3 MILLION ADDITIONAL SHARES IT IS NOTHING...10MINUTES TRADING YOU CAN SELL 3 MILLION SHARES..THIS IS NOT A DILUTION ITS RETIRING THE WARRANT/DEBENTURES ...BUT AGAIN THE EXCERCISE DATE IS NOT NOW...
Warrant No.: NEOM-0611
Number of Shares: 3,000,000
Warrant Exercise Price: $0.15
Expiration Date: June 28, 2016
Read more: http://www.faqs.org/sec-filings/110701/NEOMEDIA-TECHNOLOGIES-INC_8-K/v227725_ex10-3.htm#ixzz1RWUia7Ia
The previous CEO was the problem (Pain in ASSS) not Laura Marriot..
50 million shares needs to be covered...it's too early for the price..short may borrow more for keeping price low but eventually this will skyrocket....
Nothing wrong with NEOM.. its a legitimate company
Depository Trust & Clearing’s statistics on total failed deliv-
eries of shares to buyers show a similar trajectory: In May and June, more than 70 million shares that were sold were not delivered to buyers on an average day, the highest levels.
NEOM 70million short shares and 100% under failure to deliver..
DTC asked all brokerage to return the stock, so no matter what the agents needs to buyback the shares...by tomorrow ..
WE MIGHT SEE APPROVAL EARLIER THAN PDUFA DATE, Similar to KV.A more than a month earlier..
$1 If Matt can buyback 500K shares
Adventrx's Exelbine Could Be Available This YearMeaning 3billion$ Mkt potential
http://seekingalpha.com/article/277950-adventrx-s-exelbine-could-be-available-this-year
the aggregate worldwide market for Taxotere was in excess of $3
billion. ANX-530 (vinorelbine emulsion) is a reformulation of
Navelbine® which, despite being a generic product for a number of
years, still sells in excess of $200 million a year world-wide. Both
of the Company's product candidates have the potential to be on the
market in 2010
Read more: ADVENTRX Pharmaceuticals Inc. Exploring Strategic Options
to Maximize Company's Assets - FierceBiotech
http://www.fiercebiotech.com/press-releases/adventrx-pharmaceuticals-...
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiote...
MATT ON MONEYTV
http://www.youtube.com/user/Macbookpro3
MOST LIKELY WE ARE GETTING DOUBLE FIGURE IN NEAR FUTURE
http://www.benzinga.com/news/rumors/11/06/1197841/kv-a-pharma-receiving-positive-mention-on-turnaround-of-the-company?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29
volume died..
Pfizer wants to rule the pain killer market worldwide and ACURE is the right candidate after PTE Remoxy failure..
Aquring companies is the history and business style for Pfizer.
Soon you will hear that...
For REMOXY PTE they fought a war with KingPharma and now its gone..they would see an opportunity with OXECTA. $300 - 400 million is nothing for PFIZER.
Pfizer now might acquire Acure for $340million = $7.5 a share
ACUR NOW WOULD BE $8..$9
PFIZER HAS NO CHOICE
ANX SOUNDS GOOD,..
MKTCAP 75MILLION , 26 MILLION TOTAL O/S SHARES , $46 MILLION CASH IN HAND
the Exelbine APPROVAL = $200MILLION MKT POTENTIAL ONLY IN USA..